CanSino Biologics Inc.

Chinese drug makers have made both major cuts and additions to their R&D pipelines in recent months, including for antibody-drug conjugates (ADCs) amid increasingly fierce competition, a Scrip revie

Pfizer Inc. is divesting most rights to its Prevenar 13 vaccine (13-valent, pneumococcal polysaccharide conjugate) in China to a domestic company, in the latest localization move involving vaccines f

Chinese developers of COVID-19 antivirals and vaccines are diverging on whether to stay in the game, underscored by mixed first-half progress against the mutating SARS-CoV-2 virus. The Omicron subvari

From the early rush to get the first made in China COVID-19 vaccine to market, to the country's abrupt policy U-turn on its tough “COVID Zero” restrictions and mass infections at the end of 2022, thre